Morning Trend | Incyte experiences a decline on reduced volume, is there an impending breakout in pharmaceutical defensive stocks?

Incyte (INCY.US) has recently continued to experience a decline in trading volume, closing directly at the lower edge of the short-term consolidation range. The pharmaceutical sector has seen fluctuations this week, with market interest shifting towards high-growth themes, leading to less attention on defensive stocks. However, many defensive funds in the community prefer this bottoming state, believing that intraday fluctuations could suddenly explode. There is little news from the company, and the industry's innovation focus is on the biotechnology sector, while the main segments lack sustained highlights. Technically, INCY is currently within a medium to long-term support zone, and both the short-term RSI and momentum indicators are in the oversold area, with small-scale trial orders from dispersed funds each time it hits a new low. The key lies in sentiment and trading volume: after a volume contraction repair, pharmaceutical stocks with very low volatility can easily be lifted by speculative funds—any positive disturbance or large order movement during the session can easily trigger a return to defensive styles across the sector. Once pharmaceuticals restart as a safe-haven direction, INCY, with its deep decline and low position, can easily attract short-term funds for a quick trade. Looking back, the first wave of volume increase after each decline often marks the turning point of style. Pay attention to the trading volume and large orders in the intraday monitoring, "After the volume contraction and suppression in pharmaceutical defenses, should we get on board for the next wave of fluctuations?" is the core discussion among funds in the community